Ljubljana, 11 March (STA) - Salus, a Ljubljana-based pharmaceutical wholesaler, reported group net revenue of EUR 649 for 2024, up by 8.2% compared to 2023. Net profit grew by 26% to EUR 13 million, according to a financial report released on Tuesday.
This year Salus plans to reach net revenue of EUR 690 million and a net profit of just over EUR 12 million.
The largest company in the group, Salus Veletrgovina, further solidified its position on the Slovenian pharmaceuticals and medical equipment market last year.
Margins remained unchanged despite increasing regulatory requirements which necessitate high investment and thus high operating costs, Salus said, adding that they called on the regulator to increase margins.
Medical wholesalers were further affected by delays in hospital payments as a result of shorter payment deadlines for direct users of the state budget. Hospitals could not comply with that, which led to a higher share of overdue claims.
On 11 April Salus shareholders will vote on a proposal to allocate EUR 8.43 million of the EUR 48.72 million in distributable profit to dividends. This would amount to EUR 80 per ordinary share, an figure that includes a EUR 40 interim dividend paid out in January.
The shareholders will also decide on a proposal to increase capital to EUR 8.3 million by converting capital reserves into share capital.
